Silence Therapeutics Plc-adr (SLN) Institutional Buying & Selling Tracker (Q2 2026)

SLN ranks #5315 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

SLN is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

72 institutions disclose a position in SLN, but none treat it as a major bet — even M28 Capital Management LP, its most concentrated holder, allocates just 2.4% of its own portfolio to it.

GAMMA Investing LLC has added to its SLN position for two straight quarters, increasing it by $73.1K to reach $122.5K today.

SLN is up 0.2% today, and institutions have been net buyers of $36.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

SLN reported a net loss of $60.0M over the trailing twelve months.

• Not yet profitable — net loss of $60.0M over the trailing twelve months
• Revenue declined 97.7% year over year
• Net income improved year over year, from -$79.1M to -$60.0M
• Operating cash flow was negative, using $62.3M in cash
• Current ratio of 8.72x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.11x equity — within a conventional range